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Abstract 43 
Background:  For medical tests that have a central role in clinical decision-making, current 44 
guidelines advocate outcome-based analytical performance specifications. Given that 45 
empirical (clinical-trial style) analyses are often impractical or unfeasible in this context, the 46 
ability to set such specifications is expected to rely on indirect studies to calculate the impact 47 
of test measurement uncertainty on downstream clinical, operational and economic outcomes. 48 
Currently however, a lack of awareness and guidance concerning available alternative 49 
indirect methods is limiting the production of outcome-based specifications. Our aim 50 
therefore was to review available indirect methods and present an analytical framework to 51 
inform future outcome-based performance goals.  52 
Content:  A methodology review consisting of database searches and extensive citation 53 
tracking was conducted to identify studies using indirect methods to incorporate or evaluate 54 
the impact of test measurement uncertainty on downstream outcomes (including clinical 55 
accuracy, clinical utility and/or costs). Eighty-two studies were identified, most of which 56 
evaluated the impact of imprecision and/or bias on clinical accuracy. A common analytical 57 
framework underpinning the various methods was identified, consisting of three key steps: 58 
(1) calculation of “true” test values; (2) calculation of measured test values (incorporating 59 
uncertainty); and (3) calculation of the impact of discrepancies between (1) and (2) on 60 
specified outcomes. A summary of the methods adopted is provided, and key considerations 61 
discussed.  62 
Conclusions:  Various approaches are available for conducting indirect assessments to 63 
inform outcome-based performance specifications. This study provides an overview of 64 
methods and key considerations to inform future studies and research in this area.   65 
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Introduction 66 
Although systematic and random variation around measured test values (henceforth, 67 
measurement uncertainty) is now routinely documented within the clinical laboratory, the 68 
potential impact of this uncertainty on downstream clinical, operational and economic 69 
outcomes is rarely quantified. Meanwhile, evaluation of the impact of measurement 70 
uncertainty on clinical outcomes has become a recurring recommendation in protocols for 71 
determining analytical performance specifications. In their recently updated guidance, for 72 
example, the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) 73 
stipulate that, for medical tests that “have a central role in the decision-making of a specific 74 
disease or clinical situation and where cut-off/decision limits are established”, specifications 75 
should be based on the effect of analytical performance on the clinical outcome [termed 76 
“Model 1”], as opposed to basing specifications on biological variation [“Model 2”] or state 77 
of the art measurements [“Model 3”] (1).   78 
Two types of studies are suggested to inform specifications under Model 1: (i) direct outcome 79 
studies (i.e. analyses based solely on empirical data, such as randomised controlled trials 80 
evaluating the impact of varying analytical procedures on outcomes); or (ii) indirect outcome 81 
studies (i.e. analyses using non-empirical approaches, such as decision analytic modelling, to 82 
determine the impact of varying procedures on outcomes) (2). Since (i) is often unfeasible or 83 
impractical due to ethical, financial and time constraints associated with robust end-to-end 84 
test-outcome studies, the indirect methods of (ii) are expected to play the dominant role in 85 
this context (3). 86 
Despite general agreement that outcome-based specifications provide the best mechanism to 87 
ensure tests best serve patients’ needs, studies in this area remain uncommon. A primary 88 
reason often cited for this concerns the inherent difficulties in conducting direct outcomes 89 
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studies (1, 3). It is likely, however, that a lack of awareness and specific guidance concerning 90 
alternative indirect methods that may be employed is also a key limiting factor. The aim of 91 
this study therefore was to review methodological approaches used in previous indirect 92 
assessments and outline an analytical framework to inform future outcome-based 93 
performance specifications.  94 
Methods 95 
A literature search was conducted in November 2017 across four databases (Ovid 96 
Medline(R), Embase, Web of Science (core collection) and Biosis Citation Index) and 97 
covering a 10 year publication period (2008 to November 2017). The search was 98 
subsequently updated in 2019 (covering the period 2008 to March 2019). The search strategy 99 
(provided in the Supplemental Appendix) combined key terms relating to (a) tests, (b) 100 
measurement uncertainty, and (c) simulation/ methodology. From those studies identified via 101 
the database searches, subsequent citation tracking (including extensive backwards and 102 
forwards tracking) was conducted to identify additional studies published on any date (i.e. 103 
including studies published before 2008).  104 
Studies were included if they met the inclusion criteria shown in Table 1. Studies were 105 
required to include an assessment of downstream outcomes including: clinical accuracy (the 106 
ability of a test to distinguish between patients with and without a specified condition, or 107 
identify a change in condition), clinical utility (the ability of a test to impact on healthcare 108 
management decisions or patient health outcomes) and/or cost-effectiveness (the ability of a 109 
test to produce an efficient impact on health outcomes in relation to cost). Note that studies 110 
using indirect methods at any stage of the analysis were eligible for inclusion; this means, for 111 
example, that several method-comparison studies (an essentially empirical study design) were 112 
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nevertheless included in cases where an indirect method was subsequently used to assess the 113 
impact of identified measurement discrepancies on outcomes.   114 
<<Table 1>> 115 
All screening (including initial title/abstract screening, full text screening, and citation 116 
tracking) was conducted by the primary reviewer (AS). A data extraction form was developed 117 
(including items on key study, test, and method details) and piloted on the first 10% of 118 
included studies. Subsequent full data extraction of included studies was conducted by the 119 
primary reviewer and double checked by one of four secondary reviewers (BS, MM, CH and 120 
PH). Regular meetings with all authors were conducted to review the ongoing study findings 121 
and resolve (via group consensus) any inclusion and/or extraction uncertainties.   122 
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Results 123 
Study characteristics 124 
A total of 82 studies were identified (see Figure 1). Regarding data extraction checking, 35 125 
papers (43%) were checked by BS; 16 (20%) by CH; 16 (20%) by MM; and 15 (18%) by PH. 126 
Agreement between reviewers across extraction items was >99%.  127 
Study characteristics are summarized in Table 2, and details of measurement uncertainty 128 
components and test outcomes evaluated are provided in Table 3. Most studies focused on 129 
evaluating tests or devices used for the purposes of monitoring, diagnosis and/or screening 130 
across four key disease areas: diabetes or glycemic control, cardiovascular diseases, cancer 131 
and metabolic or endocrine disorders. Imprecision was most commonly addressed, followed 132 
by bias and total error, and studies primarily evaluated clinical accuracy outcomes.  133 
<<Figure 1>> 134 
<<Table 2>> 135 
<<Table 3>> 136 
Aim of analyses 137 
Most studies were conducted with the objective of either: (i) determining/ informing 138 
analytical performance specifications (4-22); (ii) exploring the impact of uncertainty allowed 139 
by current performance specifications (23-34); or (iii) evaluating the potential impact of 140 
measurement uncertainty on outcomes (without explicitly defining specifications) (35-78). A 141 
final group of studies consisted of “incidental” analyses, in which the impact of measurement 142 
uncertainty on outcomes was incorporated within the analysis but was not part of the primary 143 
study aim (79-85). 144 
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Methodology Framework 145 
Based on the included studies, a common analytical framework underpinning the various 146 
approaches to evaluating the impact of measurement uncertainty on outcomes was identified. 147 
This framework consists of three key steps: (1) calculation of “true” test values; (2) 148 
calculation of measured test values (i.e. incorporating measurement uncertainty); and (3) 149 
calculation of the impact of discrepancies between (1) and (2) on the outcome(s) under 150 
consideration. An outline of the various methods adopted within this framework is provided 151 
below and summarized in Figure 2. A summary table detailing the methods used in each 152 
individual study is provided in Supplemental Table 1.  153 
1. Step one: calculation of “true” test values 154 
Calculation of “true” test values was based either on empirical data values (5, 7, 9-11, 18, 21, 155 
26, 30-32, 34-37, 39-42, 45, 49-53, 56-58, 60, 61, 64, 66-69, 71, 74, 77, 78, 85) and/or 156 
simulated values (4-6, 8, 12-17, 19, 20, 22-25, 27-29, 33, 36, 38, 43, 44, 46-48, 54, 55, 59, 157 
62, 63, 65, 70, 72-76, 79-84).  158 
Studies using empirical data here included: (i) method comparison and external quality 159 
assessment (EQA) studies, which utilized indirect methods to determine the impact of 160 
discrepancies between empirical reference (i.e. “true”) test measurements vs. index (i.e. 161 
uncertain) test measurements on specified outcomes (e.g. using the “error grid” approach 162 
outlined in Step 3) (35, 37, 41, 42, 51, 53, 56-58, 60, 64, 66-69, 71, 75, 78); and (ii) studies 163 
which derived uncertain measurements from “true” empirical data values using various (non-164 
empirical) approaches outlined in Step 2 (5, 7, 9-11, 18, 21, 26, 30-32, 34, 36, 39, 40, 45, 48-165 
50, 52, 61, 77, 85).  166 
Studies using simulation methods here used a range of approaches – the simplest of which 167 
was to assume a fixed set of individual “true” values specified across the measurement range 168 
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and simulate uncertainty around these values (see Step 2) (12, 16, 27, 33, 36, 38, 79, 83, 84). 169 
Whilst this approach does not require any simulation for the “true” measurements per se, the 170 
values here are nevertheless generated rather than using real-world data directly. An 171 
extension of this approach is to assume a uniform distribution to describe the “true” 172 
frequency distribution(s): that is, assume a constant probability of occurrence for each test 173 
value along a specified measurement range, and draw from this distribution within the 174 
simulation (14, 17, 19, 44, 55). Alternatively, the expected likelihood of test values was often 175 
modelled using Gaussian (i.e. normal) or log-Gaussian frequency distributions, specified 176 
using published or empirical data on the expected mean and variance of test values (4-6, 8, 177 
13-15, 20, 46, 47, 59, 63, 65). Other infrequently adopted parameterizations included mixed 178 
Gaussian distributions (54, 62), multivariate Gaussian distributions (where correlations 179 
between tests are known (43)) and the exponential distribution (82). Non-parametric 180 
simulation approaches were also used, based on sampling with replacement from an 181 
empirical dataset (18, 30). Finally, several studies used simulation techniques (22, 23, 70, 74, 182 
75), or utilized findings from previously published simulation studies (24, 25, 73, 76), but did 183 
not clearly report details regarding the calculation of “true” baseline values.   184 
An important issue with respect to the estimation of “true” test values concerns how well the 185 
underlying data may be considered a reliable proxy for the truth. A handful of studies 186 
attempted to directly address this issue, by “stripping” known measurement uncertainty from 187 
baseline “true” test values via statistical adjustment: imprecision, for example, can be 188 
removed from the variance term of a specified Gaussian/log-Gaussian distribution using a 189 
reverse form of the “sum of squares rule”; whilst bias can be removed from the mean term (7-190 
10, 13, 15, 31). In general, however, the likelihood that the adopted “true” test values would 191 
in fact be representative of the truth was either implicitly assumed or not discussed.  192 
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2. Step two: calculation of measured test values (incorporating measurement 193 
uncertainty) 194 
Approaches to the calculation of measured test values predominantly fell into four broad 195 
categories: (1) empirical assessment (35, 37, 41, 42, 51, 53, 56-58, 60, 64, 66-69, 71, 74, 78), 196 
(2) graphical assessment (5, 7, 9-11, 36), (3) computer simulation (4-6, 8, 12, 14-25, 27-31, 197 
34, 38, 39, 44, 46, 49, 50, 52, 54, 55, 59, 61-63, 65, 70, 72-77, 79-85), or regression analysis 198 
(26, 32, 43, 47).   199 
Studies using empirical assessment here included method-comparison studies (35, 37, 41, 42, 200 
53, 56-58, 60, 64, 66-69, 71, 75, 78) and an EQA study (51) which based “true” test values 201 
on the specified reference test and measured values on the index test measurements.   202 
An alternative method, first appearing in 1980, is based on applying hypothetical 203 
measurement uncertainty to “true” values via graphical manipulation (5, 7, 9-11, 36). This 204 
approach centers on plotting the cumulative percentage frequency of “true” values on the 205 
probit scale (x-axis) as a function of “true” values on the logarithmic scale (y-axis); assuming 206 
that the log-transformed data are Gaussian, then in the bimodal case (where healthy and 207 
diseased populations are modeled separately), cumulating the healthy (diseased) population 208 
from high (low) values results in two straight lines sloping in opposite directions for each 209 
population (i.e. forming an ‘X’ on the plot).  The addition of negative (positive) bias is then 210 
explored by shifting the straight lines to the left (right) on the x-axis; whilst the addition of 211 
imprecision is explored by rotating each line around their mean value (i.e. broadening the 212 
95% confidence interval of the values on the probit scale). Given a specified cut-off 213 
threshold, the proportion of false positives and negatives at a particular level of bias and 214 
imprecision can be read off directly from this plot, by observing the point at which 215 
healthy/diseased populations cross the threshold line.   216 
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In response to modern computational capabilities, the graphical method has been superseded 217 
by computer simulation approaches which can accommodate more complex specifications of 218 
the measurand distribution and measurement uncertainty. The most flexible and widely 219 
adopted approach in the identified studies was based on iterative simulation, with uncertainty 220 
added on to “true” test values according to a specified error model – a function relating 221 
measured test values to baseline “true” values plus specified components of measurement 222 
uncertainty (14, 17-19, 28-30, 34, 54, 62, 79, 82-84). This method is largely attributed to the 223 
seminal 2001 paper by Boyd and Bruns (14) – the first study of this kind to clearly specify 224 
the error model as a mathematical function (as opposed to earlier (4-6) and later (21-25, 44, 225 
49, 52, 70, 72, 73, 76, 77, 80, 81, 85) studies limited to textual descriptions or indirect 226 
referencing). An example of a typical error model is as follows:  227 
Testmesaured   =   Testtrue  +  [ Testtrue * N(0,1) * CV ]  +  Bias            (1) 228 
where Testtrue is the “true” measurement value; Testmeasured is the observed test value 229 
measured with imprecision (coefficient of variation [CV%]) and absolute bias (Bias); and 230 
N(0,1) is a normal distribution (mean = 0, standard deviation [SD] = 1) applied with the 231 
CV% value in order to produce a spread of Gaussian-distributed results around Testtrue.  232 
The error model iterative simulation approach works as follows: (i) a random draw is taken 233 
from the distribution of “true” values to generate a value for Testtrue; (ii) components of 234 
measurement uncertainty are applied to Testtrue according to the error model formula to 235 
simulate a value for Testmeasured (this may require random number draws – for example in 236 
equation (1) a random draw from N(0,1) is required for the application of imprecision); (iii) 237 
points (i) and (ii) are repeated (e.g. 10,000 times to simulate 10,000 Testtrue and Testmeasured 238 
values) for a given level of measurement uncertainty (e.g. CV% = 5% and Bias = 5%); and 239 
(iv) points (i) to (iii) are repeated for varying levels of measurement uncertainty (e.g. CV% 240 
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ranging from 0-20% and Bias ranging from +/-10% in 1% increments). This iterative process 241 
can be efficiently implemented using standard statistical software, such as Excel or R.  242 
Rather than iteratively adding on uncertainty via error model simulation, an alternative 243 
approach is to incorporate uncertainty directly within a specified probability distribution (e.g. 244 
incorporating bias within the mean term, and imprecision within the variance term of a 245 
Gaussian or log-Gaussian distribution). This distribution can be applied iteratively around 246 
individual “true” values (12, 16, 18, 27, 30, 38, 46, 59, 61), or at a population level, by 247 
adjusting a specified “true” population distribution to include additional uncertainty (8, 15, 248 
31, 63, 65).  249 
The remaining studies used regression analysis (26, 32, 43, 47), other one-off methods (12, 250 
13, 33, 40, 45, 48), or reported insufficient details regarding simulation techniques to 251 
determine the exact method employed (74, 75). Within the identified regression analyses, 252 
bias or total error was applied as a multiplicative factor to baseline measurements within a 253 
specified regression model, with the resulting impact on the regression output (e.g. likelihood 254 
ratio) explored. Details of studies using other one-off/ indeterminate methods can be found in 255 
Supplemental Table 1.    256 
3. Step three: calculation of the impact on test outcomes  257 
The final step is to assess the impact of deviations between “true” and measured values on the 258 
outcome(s) of interest.  259 
Most studies focused on evaluating clinical accuracy (4-13, 15, 16, 20, 26-29, 31-33, 38, 39, 260 
43, 45-52, 55, 59, 61-63, 65, 79-85). In this case the calculation is generally straightforward: 261 
the rate of change in mis-categorizations (e.g. false positive/negative diagnoses) is 262 
determined according to the change in the proportion of measured values pushed above or 263 
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below the given test cut-off threshold(s) used to define disease status or inform treatment 264 
decisions, compared to the “true” value classifications. This was the typical approach taken in 265 
studies using the graphical and simulation approaches outlined in Step 2, for example.  266 
Several studies evaluated the impact of measurement uncertainty on treatment management 267 
decisions (14, 18, 21, 30, 35, 37, 41, 42, 51, 53, 56-58, 60, 64, 66-69, 71, 74, 75, 78). Most of 268 
these were method-comparison studies which determined the impact of measurement 269 
deviations on treatment decisions using error grid analysis (35, 37, 41, 42, 53, 56-58, 60, 64, 270 
66-69, 71, 74, 78). Two studies similarly employed the error grid approach, but used 271 
simulated (rather than empirical) reference and index test measurements (74, 75). First 272 
developed in the 1980s, the original error grid aimed to evaluate the potential impact of 273 
measurement discrepancies between self-monitoring blood glucose devices and laboratory 274 
reference measurements in terms of insulin dosing errors (35). Using a scatter plot of 275 
reference vs. index test measurements, the plot was divided into five error grid “zones” 276 
according to assumed severity of associated dosing errors (from zone A = clinically accurate 277 
results; to zone E = erroneous results leading to dangerous failure to detect and treat). More 278 
recently studies have attempted to build on this approach, for example by expanding on the 279 
small sample of experts used to define the initial error grid (37, 74, 75), accounting for 280 
temporal aspects of measurement (41), or applying the same methodology to alternative 281 
clinical settings (64).  282 
Others have attempted to incorporate the impact of measurement uncertainty on patient health 283 
outcomes (17, 19, 22, 23, 44, 54, 70, 72). All of these studies related to evaluations of 284 
monitoring devices for glycemic control, in which health outcomes such as hypoglycemia 285 
and hyperglycemia were determined using decision analytic models based around sequential 286 
glucose measurements (incorporating measurement uncertainty via the error model 287 
simulation approach, for example). Combined with data on insulin dose administrations 288 
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(resulting from measured values), and additional factors such as patient insulin sensitivity and 289 
gluconeogenesis, these models were used to track patients’ response to administered doses 290 
and resulting health outcomes.  291 
Nine final studies included an assessment of costs or cost-effectiveness (7, 8, 11, 24, 25, 40, 292 
73, 76, 77). Four were based on a simple assignment of expected costs of misdiagnoses to 293 
rates of false positive/negative results (7, 8, 11), or expected costs of adverse events applied 294 
to simulated health outcomes data (77). One study included a more comprehensive costing 295 
analysis, in which the potential financial implications of calibration bias in serum calcium 296 
testing was explored (40). The remaining four studies all utilized the previous work of Breton 297 
and Kovatchev (2010), in which the impact of reduced glucose meter imprecision on 298 
glycemic events was simulated using a published simulation platform (23). Two studies 299 
constructed simple cost-consequence decision models, combining the Breton and Kovatchev 300 
(2010) findings with data on patient population numbers, glucose meter costs, and the rate of 301 
myocardial infarctions resulting from glycemic outcomes, to estimate annual cost savings 302 
associated with improved meter precision (73, 76). Two more recent studies conducted full 303 
cost-effectiveness analyses, using cohort Markov (i.e. state-transition) models to link the data 304 
on improved glycemic control and reduced glycemic event rates, with data on diabetes 305 
complication rates, patient health-related quality of life and health service costs (24, 25). 306 
Using these models the authors were able to estimate the incremental cost per additional 307 
quality adjusted life year (QALY) associated with reduced device error.   308 
<<Figure 2>> 309 
  310 
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Discussion 311 
Review findings 312 
Based on our methodology review findings, a three-step analytical framework underpinning 313 
the various approaches to determining the impact of measurement uncertainty on outcomes 314 
was identified (see Figure 2). Key points for consideration within this framework are 315 
discussed below.  316 
With regards to Step 1 (calculation of “true” test values), the primary advantage of using 317 
either empirical data or informed parametric distributions is that, by accounting for the 318 
expected frequency of values, population-level conclusions (such as analytical performance 319 
specifications) may be derived. In contrast, the primary drawback of the fixed-values 320 
approach, and by extension the uniform distribution approach (assuming this is not a realistic 321 
parameterization), is that population-level conclusions cannot be derived. Nevertheless, such 322 
approaches may be useful for exploring the impact of measurement uncertainty in specific 323 
scenarios – for example, to explore the impact of uncertainty on test values close to the test 324 
cut-off threshold.   325 
A question that must be considered when using either empirical or parametric distributions, is 326 
how well the underlying data may be considered to represent the truth. If values used to 327 
inform the “true” distributions are themselves subject to measurement uncertainty (even if 328 
this uncertainty is expected to be small), then all subsequent analyses may be affected by this 329 
confounding factor and care should be taken when asserting absolute maximum bounds for 330 
imprecision and bias. A handful of studies did attempt to address this issue using statistical 331 
adjustment methods however this approach depends on having reliable information on the 332 
expected measurement uncertainty contained in the baseline “true” measurement values and 333 
can only be used when modelling test values as parametric distributions (7-10, 13, 15, 31).  334 
 Evaluating the impact of measurement uncertainty 
 
17 
 
A second consideration in the adoption of parametric distributions concerns the 335 
appropriateness of the assumed parametric form. Whilst a minority of studies provided some 336 
form of justification for the parametric choice (e.g. using the Kolmogorov–Smirnov test for 337 
normality), a common implicit assumption was that data would be likely to be Gaussian or 338 
log-Gaussian distributed. The validity of this assumption is not always clear, however.  339 
Within Step 2 (calculation of measured test values) computer simulation methods offer the 340 
most flexible approach for exploring alternative specifications and levels of measurement 341 
uncertainty. In the context of setting performance goals, studies based on method-comparison 342 
analyses are of limited use given the fact that alternative levels of measurement uncertainty 343 
cannot be efficiently explored, and analyses using the graphical method suffer from the issue 344 
that non-Gaussian parameterisations or non-constant/ non-linear specifications of bias or 345 
imprecision cannot be accommodated. The error model approach is particularly useful in this 346 
respect. While the example formula provided in Equation (1) specifies one CV% element 347 
representing total imprecision, additional elements of imprecision (e.g. pre-analytical, 348 
analytical and biological) may be separately specified. Alternative characterisations of 349 
imprecision may also be defined: for example, using (i) a fixed SD, (ii) different SD/CV 350 
values for different sections of the measurement range, or (iii) imprecision defined as a 351 
linear/ non-linear function of Testtrue. Similarly bias may also be characterised in alternative 352 
ways.   353 
With regards to Step 3 (calculation of the impact on outcomes), a further advantage of the 354 
simulation approach is that, by sampling over a range of bias and imprecision values, the 355 
joint impact of these components on outcomes can be clearly explored. In particular, several 356 
studies used contour plots to present their findings (14-19, 21, 30, 34, 62): an example, 357 
provided in Figure 3, represents a hypothetical case in which bias and imprecision have been 358 
applied (according to equation (1)) to normally distributed healthy [N(30,5)] and diseased 359 
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[N(60,10)] populations. The plotted lines indicate at which values of imprecision and bias a 360 
given value of clinical sensitivity/specificity is maintained. For example in this case, at 361 
imprecision=0, increasing positive bias decreases clinical specificity and increases clinical 362 
sensitivity, whilst negative bias has the opposite effect. Based on this plot, we expand on the 363 
typical contour plot to show how maximum allowable bounds for imprecision and bias can be 364 
identified according to specified minimum requirements for clinical accuracy. Suppose, for 365 
example, that we require sensitivity to remain above 90% and specificity to remain above 366 
80% in order to maintain expected health utility gains. The region of acceptable analytical 367 
bias and imprecision values for this specification of clinical accuracy is illustrated by the 368 
shaded region of the contour plot – from this we can see that, if bias is zero we can tolerate 369 
up to 20% imprecision, whilst if imprecision is zero we can tolerate -8 to +6 units of absolute 370 
bias. Plots such as this one offer an effective means of highlighting acceptable bounds for 371 
measurement uncertainty.  372 
<<Figure 3>> 373 
Whilst most studies focused on the intermediate outcome of clinical accuracy, ideally 374 
technologies should be evaluated in terms of their influence on “end-point” outcomes i.e. 375 
health outcomes (clinical utility), operational and/or cost-effectiveness outcomes. Several of 376 
the identified studies utilized analytic decision modeling techniques to determine the impact 377 
of measurement uncertainty on health outcomes: while these all related to the context of 378 
glycemic control devices, decision models can feasibly be used to explore any clinical 379 
pathway of interest, subject to data availability. Within the field of health technology 380 
assessment, for example, decision models are routinely employed to evaluate the expected 381 
clinical utility and cost-effectiveness of novel tests, by linking data on disease prevalence and 382 
test clinical accuracy (e.g. the proportion of correct and incorrect diagnoses), with 383 
downstream data on the expected change in patient management, patient compliance to 384 
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treatment and treatment effectiveness (often referred to as the “linked-evidence approach”) 385 
(86-88). Although this approach is more resource- and data-intensive, and care must be taken 386 
to ensure that the model structure appropriately reflects key aspects of the clinical pathway, it 387 
nevertheless has the advantage of explicitly capturing the impact of additional parameters 388 
(e.g. treatment effectiveness) on end-point outcomes (which may not always produce 389 
expected or intuitive results) and uncertainty around the exact values of these parameters can 390 
be quantitatively characterised in the model framework (89). We identified two recent studies 391 
which utilized health-economic models to estimate the cost-effectiveness of improved 392 
analytical performance (24, 25). These studies explored a limited set of fixed imprecision 393 
levels relating to pre-existing performance specifications: future studies could extend this 394 
methodology to explore a broader range of measurement uncertainty values (e.g. by linking 395 
error-model simulations with the downstream health-economic modelling) and derive de 396 
novo performance specification based on maintaining or optimizing cost-utility and cost-397 
effectiveness outcomes.   398 
Strengths and limitations:  399 
In light of the sustained international focus on outcome-based analytical performance 400 
specifications, it is expected that the indirect approaches outlined in this study will become 401 
increasingly important. The analytical framework presented in this study provides a useful 402 
starting point to inform future studies in this area, by clearly outlining available methods in 403 
sufficient detail to enable practical implementation, and highlighting possible advantages and 404 
limitations to consider under each approach. Whereas previous studies have provided 405 
commentaries and general reviews of various approaches to setting analytical performance 406 
specifications (3, 90, 91), this is the first methodology review to focus specifically on indirect 407 
methods for setting outcome-based performance specifications.  408 
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As a methodology review, the aim of this study was not to systematically identify all 409 
evidence, but rather to ensure that key examples of relevant methods were identified. While 410 
we attempted to make the database search as sensitive as possible, due to the vast volume of 411 
literature in this area we necessarily had to focus the search strategy by: (i) concentrating on 412 
terms related to in-vitro biomarkers, (ii) including a filter for simulation and methodology 413 
terms, and (iii) restricting the initial database search period to 10 years. Extensive citation 414 
tracking was additionally conducted, extending into preceding years, in order to ensure that 415 
seminal papers informing modern practices would be identified in addition to current state-of-416 
the-art methodology. Although we believe that this two-stage strategy will have captured key 417 
methodologies, not all relevant material relating to each method will have been identified and 418 
we cannot therefore draw definitive conclusions regarding the frequency that each method 419 
has been used. Nevertheless, we believe our findings provide a valuable overview of indirect 420 
study methods and an informative starting point for future studies in this area.  421 
422 
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Tables 709 
Table 1. Review inclusion criteria 710 
Population Any human population with any indication 
Intervention 
In-vitro test (excluding imaging) or any kind of medical 
device used for the purpose of screening, diagnosis, 
prognosis, monitoring or predicting treatment response 
Comparator Any 
Outcomes 
(a) Clinical accuracy e.g.  
- Diagnostic sensitivity and/or specificity 
- Positive/negative predictive values 
- ROC curve/ AUC analysis 
- Relative risks 
- Likelihood ratios 
(b) Clinical utility 
- Impact on treatment management 
decisions 
- Impact on patient health outcomes 
(c) Costs 
(d) Cost-effectiveness 
Method 
Analysis includes indirect methods (i.e. excluding purely 
empirical analyses) to incorporate or assess the impact of 
one or more components of measurement uncertainty 
(below) on one or more outcomes (above):  
- Bias (e.g. calibration or method bias) 
- Imprecision (e.g. repeatability, within-
laboratory or between-laboratory 
imprecision)   
- Pre-analytical or analytical effects 
- Summary metrics (e.g. total error [TE] or 
uncertainty of measurement [UM]) 
Study type Full paper relating to an original study 
Language Full text in English 
Year of 
publication 
Database search: January 2008 – March 2019 
Citation tracking: any data  
ROC = Receiver operator characteristic; AUC = Area under the curve  
  711 
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Table 2. Study characteristics 712 
 N % 
Year of publication 
Pre-2008 (identified via citation 
tracking alone) 
25 30% 
2008 – 2009  3 4% 
 2010 – 2011 7 9% 
2012 – 2013 9 11% 
2014 – 2015  18 22% 
2016 – 2017  13 16% 
2018-2019 7 9% 
Clinical areaa 
Diabetes & glycemic control 43 52% 
Cardiovascular diseases  17 21% 
Cancer 10 12% 
Metabolic & endocrine 
disorders 
8 10% 
Kidney disorders 3 4% 
Prenatal screening 3 4% 
Noise induced hearing loss 2 2% 
Role of testa 
Monitoring 44 54% 
Diagnosis 24 29% 
Screening 11 13% 
Prognosis 7 9% 
aSeveral studies included a test or tests used in multiple clinical areas or roles (hence 
total percentages under these categories sum to >100%).  
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Table 3. Components of measurement uncertainty included and test outcomes assessed  714 
 N % 
Component(s) of measurement uncertainty includeda 
Imprecision:   
Analytical 31 38% 
Pre-analytical / combined pre-
analytical and analytical 
8 10% 
Non-specific 11 13% 
Total 50 61% 
Bias:   
Analytical 18 22% 
Calibration bias 9 11% 
Non-specific 9 11% 
Pre-analytical / combined pre-
analytical and analytical 
2 2% 
Between-method bias 1 1% 
Total 39 48% 
Total error:   
Method-comparison study 18 22% 
EQA study 2 2% 
Other 6 7% 
Total 26 32% 
Biological variation included? 
Yes - included as a separate element 13 16% 
Yes - combined with imprecision 5 6% 
Total 18 22% 
Primary test outcome assesseda   
Clinical accuracy 45 55% 
Clinical utility:   
Impact on treatment management 23 28% 
Impact on health outcomes 13 16% 
Costs 7 9% 
Cost-effectiveness 2 2% 
a several studies included multiple components of measurement uncertainty or 
assessed multiple test outcomes (hence total percentages under these categories 
sum to >100%). 
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Figure captions 716 
Figure 1. PRISMA flow diagram of included studies 717 
Figure 2. Summary box outlining the three-step analytical framework, primary methods 718 
identified for each step in the framework, and key questions for consideration in future 719 
analyses 720 
Figure 3. Example contour plot based on simulations using the error model approach (adding 721 
increasing magnitudes of bias and imprecision onto assumed “true” measurand values). The 722 
contour lines indicate what level of clinical accuracy is achieved across the range of bias and 723 
imprecision inputs explored: varying sensitivity levels as a function of bias and imprecision 724 
are represented by the solid contour lines, whilst varying specificity levels are represented by 725 
the dashed contour lines.  The grey region represents an “acceptability region” for bias and 726 
imprecision, which maintains sensitivity ≥ 90% and specificity ≥ 80%.  727 
